View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK300.00) - Headwinds set to persist in Q1

We forecast Q1 organic sales growth of just 0.6% YOY, below the full-year guidance, owing to persistent headwinds in wholesale. However, with Managed Care headwinds set to annualise from Q2, better quarters should lie ahead. We expect an unchanged 2025 guidance of 3–7% organic sales growth and DKK4.5bn–4.9bn in EBIT, but we find the lower end most likely. We reiterate our BUY but have cut our target price to DKK300 (320).

Oliver Metzger
  • Oliver Metzger
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK320.00) - Back-end-loaded 2025e recovery

Demant ended the year at the low end of its guidance, with H2 organic growth of c2% YOY and EBIT before special items of DKK2,336m. While we see scope for a recovery in 2025, we forecast it to be back-end loaded, supported by easing headwinds related to Managed Care from Q2e. The 2025 guidance is for 3–7% organic sales growth and EBIT of DKK4.5bn–4.9bn. We reiterate our BUY, but have cut our target price to DKK320 (330).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK330.00) - Headwinds set to ease in 2025

We forecast 2.2% organic revenue growth YOY in Q4 (consensus 2.3%) and H2 EBIT before special items of DKK2,312m (consensus DKK2,310m), implying 2024 earnings at the lower end of the guidance. We expect Demant to guide for 3–7% organic revenue growth and EBIT of DKK4.6bn–5.0bn for 2025, with easing headwinds (Managed Care and competitive pressure). We reiterate our BUY and DKK330 target price.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch